Denali Therapeutics Operating Expenses Growth & History (DNLI)

Denali Therapeutics's operating expenses was $555.3M for fiscal 2025.

View full Denali Therapeutics company overview

Denali Therapeutics annual operating expenses history

Denali Therapeutics annual operating expenses

Fiscal yearPeriod endedOperating expensesChangeGrowth
20252025-12-31$555.3M$53.5M+10.65%
20242024-12-31$501.9M−$25.4M−4.81%
20232023-12-31$527.2M$78.0M+17.37%
20222022-12-31$449.2M$104.8M+30.43%
20212021-12-31$344.4M$71.5M+26.19%
20202020-12-31$272.9M$33.1M+13.79%
20192019-12-31$239.9M$64.3M+36.65%
20182018-12-31$175.5M$85.4M+94.73%
20172017-12-31$90.1M$2.7M+3.10%
20162016-12-31$87.4M

Denali Therapeutics operating expenses trends

Over the last five fiscal years, Denali Therapeutics's operating expenses increased from $272.9M to $555.3M, a change of $282.4M. The latest reported quarter, Q2 2026, shows $134.1M.

About the metric

What operating expenses mean

Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.

Calculation and source

SEC-reported and calculated operating expenses

TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Denali Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about DNLI yet. Start the conversation.

Write the first post